Scarica l'app Stockscreener
30.19
0.97%
0.29
Pre-mercato:
28.00
-2.19
-7.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Can Stoke Therapeutics Inc. rally from current levelsGlobal Markets & Stepwise Trade Execution Plans - newser.com
Is a relief rally coming for Stoke Therapeutics Inc. holders2025 Buyback Activity & Consistent Profit Focused Trading Strategies - newser.com
Stoke Therapeutics Hits New 52-Week High at $32.40, Up 104.84% - Markets Mojo
Edward Md Kaye Sells 25,000 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Needham & Company LLC - MarketBeat
Why Stoke Therapeutics (STOK) Is Up 18.1% After Positive Three-Year Data for Dravet Syndrome Therapy - simplywall.st
Stoke therapeutics director Kaye sells $750,000 in shares By Investing.com - Investing.com South Africa
Stoke therapeutics director Kaye sells $750,000 in shares - Investing.com
Biogen and Stoke add to zorevunersen data package in Dravet syndrome - The Pharma Letter
Needham raises Stoke Therapeutics stock price target to $35 on positive trial data - Investing.com Canada
Biogen, Stoke Therapeutics Present Positive Long-Term Data for Zorevunersen in Dravet Syndrome - MarketScreener
What is Leerink Partnrs' Estimate for STOK FY2027 Earnings? - MarketBeat
Needham Maintains Stoke Therapeutics (STOK) Buy Recommendation - Nasdaq
Needham Raises Stoke Therapeutics (STOK) Price Target by 59.09% to $35 | STOK Stock News - GuruFocus
Will Stoke Therapeutics Inc. price bounce be sustainableJuly 2025 Catalysts & Smart Swing Trading Alerts - newser.com
How to integrate Stoke Therapeutics Inc. into portfolio analysis tools - newser.com
Using data tools to time your Stoke Therapeutics Inc. exitJuly 2025 Decliners & AI Optimized Trading Strategy Guides - newser.com
Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome - Nasdaq
Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome - Yahoo
Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Sy - GuruFocus
Biogen and Stoke Therapeutics Announce Positive Long-Term Results of Zorevunersen in Dravet Syndrome at Child Neurology Society Annual Meeting - Quiver Quantitative
Biogen and Stoke Therapeutics Present New Data at the 54th - GlobeNewswire
Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - MarketScreener
Stoke Therapeutics Hits Day High with 11.68% Surge in Stock Price - Markets Mojo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39% - simplywall.st
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 39% But Its Business Still Trails The Industry - 富途牛牛
Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? - Yahoo Finance
Detecting price anomalies in Stoke Therapeutics Inc. with AIRate Cut & Fast Gain Swing Trade Alerts - newser.com
What the charts say about Stoke Therapeutics Inc. todayGlobal Markets & Real-Time Stock Entry Alerts - newser.com
Signal strength of Stoke Therapeutics Inc. stock in tech scannersEarnings Risk Summary & Reliable Trade Execution Plans - newser.com
Stoke Therapeutics (NASDAQ:STOK) Given "Sell (D+)" Rating at Weiss Ratings - MarketBeat
Will Stoke Therapeutics Inc. stock gain from lower inflation2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Stoke Therapeutics’ Stock Climbs: What’s Next? - timothysykes.com
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Stoke Therapeutics stock hits 52-week high at 28.03 USD By Investing.com - Investing.com Canada
Stoke Therapeutics stock hits 52-week high at 28.03 USD - Investing.com
Stoke Therapeutics Hits New 52-Week High at $28.00, Up 80% - Markets Mojo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 10,000 Shares - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells 42,461 Shares - MarketBeat
Stoke Therapeutics Appoints Ian F. Smith as CEO - The Globe and Mail
Stoke Therapeutics Hits New 52-Week High of $25.61, Up 71.66% - Markets Mojo
Stoke Therapeutics appoints Ian Smith as permanent CEO By Investing.com - Investing.com Canada
Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
Stoke Therapeutics (NASDAQ:STOK) Sets New 12-Month HighStill a Buy? - MarketBeat
Stoke Therapeutics, Inc. Appoints Ian F. Smith as Chief Executive Officer - MarketScreener
Stoke Therapeutics Inc.’s volatility index tracking explainedMarket Activity Recap & Precise Entry and Exit Recommendations - newser.com
Stoke Therapeutics (STOK) Appoints Ian F. Smith as CEO - GuruFocus
Stoke Therapeutics names Ian F. Smith as permanent CEO and principal executive - Investing.com
Stoke Therapeutics appoints Ian Smith as permanent CEO - Investing.com India
Stoke Therapeutics appoints Ian Smith as chief executive officer - MarketScreener
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer - The Globe and Mail
Quantitative breakdown of Stoke Therapeutics Inc. recent move2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
Using flow based indicators on Stoke Therapeutics Inc.Market Sentiment Report & Technical Pattern Alert System - newser.com
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Why Stoke Therapeutics Inc. stock is a must watch in 20252025 Short Interest & Stock Market Timing Techniques - newser.com
Is Stoke Therapeutics Inc. a candidate for recovery play2025 Earnings Surprises & High Return Stock Watch Alerts - newser.com
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):